Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aileron Therapeutics Inc (NQ: ALRN ) 1.890 +0.240 (+14.55%) Streaming Delayed Price Updated: 3:59 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Aileron Therapeutics Inc Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights May 15, 2024 From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics to Present at Two Upcoming Investor Conferences May 06, 2024 From Aileron Therapeutics, Inc. Via GlobeNewswire BioMedNewsBreaks — Aileron Therapeutics Inc. (NASDAQ: ALRN) Closes Underwritten Registered Direct Offering May 06, 2024 Via Investor Brand Network Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million May 03, 2024 Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million May 01, 2024 Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) May 01, 2024 From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics Inc. (NASDAQ: ALRN) Leading the Way in Thursday Trading Based on Percentage Gain April 18, 2024 Via Investor Brand Network Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update April 15, 2024 From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics Announces CEO Transition March 12, 2024 From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event February 15, 2024 Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 February 01, 2024 Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives February 21, 2023 From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements November 30, 2022 From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split November 10, 2022 Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022 From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights November 01, 2022 From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference October 26, 2022 From Aileron Therapeutics, Inc. Via GlobeNewswire Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022 September 30, 2022 From Aileron Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.